Artiva Biotherapeutics (ARTV) Registration Filing summary

Company overview and business model

• Clinical-stage biotech developing allogeneic, off-the-shelf NK cell therapies for autoimmune diseases and cancers.

• Lead candidate AlloNK is a non-genetically modified, cryopreserved NK cell therapy, evaluated with B-cell targeted mAbs in SLE, LN, and B-NHL.

• Proprietary manufacturing platform enables scalable, cost-effective production; strategic partnership with GC Cell for technology and manufacturing.

• Pipeline includes AlloNK and CAR-NK candidates for multiple indications, with both company- and collaborator-funded trials.

• Mission to develop effective, safe, and accessible cell therapies for patients with high unmet needs.

Financial performance and metrics

• 2023 revenue: $33.5M (mainly from Merck collaboration, which was terminated in October 2023); 2022 revenue: $4.9M.

• 2023 net loss: $28.7M; 2022 net loss: $58.8M.

• Q1 2024 net loss: $14.0M; Q1 2023 net loss: $16.7M.

• Cash, cash equivalents, and short-term investments as of March 31, 2024: $62.1M.

• Accumulated deficit as of March 31, 2024: $195.3M.

• Pro forma post-IPO cash position estimated at $178.9M, with pro forma as adjusted stockholders’ equity of $183.9M.

Use of proceeds and capital allocation

• Estimated net proceeds of $116.8M (or $135.0M if underwriters’ option exercised in full) at $15.00/share midpoint.

• ~$55M allocated to clinical development of AlloNK, including initial data from Phase 1/1b SLE/LN trial and basket IIT.

• Remainder for discovery, preclinical development, headcount, manufacturing, working capital, and general corporate purposes.

• Funds expected to support operations into late 2026; substantial additional capital will be needed for further development and commercialization.